By-passing in vitro screening-next generation sequencing technologies applied to antibody display and in silico candidate selection

被引:134
作者
Ravn, U. [1 ]
Gueneau, F. [1 ]
Baerlocher, L. [2 ]
Osteras, M. [2 ]
Desmurs, M. [1 ]
Malinge, P. [1 ]
Magistrelli, G. [1 ]
Farinelli, L. [2 ]
Kosco-Vilbois, M. H. [1 ]
Fischer, N. [1 ]
机构
[1] Novlmmune SA, CH-1228 Plan Les Ouates, Switzerland
[2] Fasteris SA, CH-1228 Plan Les Ouates, Switzerland
关键词
PHAGE-DISPLAY; ANTIGEN INTERACTIONS; FUNCTIONAL PROTEINS; LIBRARY; AFFINITY; REPERTOIRE; PROTEOMICS; CLONING; DESIGN;
D O I
10.1093/nar/gkq789
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library designed to confine diversity to both CDR3, > 1.9 x 10(7) sequences have been generated. This approach allowed for in depth analysis of the library's diversity, provided sequence information on virtually all scFv during selection for binding to two targets and a global view of these enrichment processes. Using the most frequent heavy chain CDR3 sequences, primers were designed to rescue scFv from the third selection round. Identification, based on sequence frequency, retrieved the most potent scFv and valuable candidates that were missed using classical in vitro screening. Thus, by combining NGS with display technologies, laborious and time consuming upfront screening can be by-passed or complemented and valuable insights into the selection process can be obtained to improve library design and understanding of antibody repertoires.
引用
收藏
页数:11
相关论文
共 39 条
[1]   Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires [J].
Almagro, JC .
JOURNAL OF MOLECULAR RECOGNITION, 2004, 17 (02) :132-143
[2]   In vitro display technologies:: novel developments and applications [J].
Amstutz, P ;
Forrer, P ;
Zahnd, C ;
Plückthun, A .
CURRENT OPINION IN BIOTECHNOLOGY, 2001, 12 (04) :400-405
[3]   Engineering novel binding proteins from nonimmunoglobulin domains [J].
Binz, HK ;
Amstutz, P ;
Plückthun, A .
NATURE BIOTECHNOLOGY, 2005, 23 (10) :1257-1268
[4]   Antibodies in proteomics II: screening, high-throughput characterization and downstream applications [J].
Bradbury, A ;
Velappan, N ;
Verzillo, V ;
Ovecka, M ;
Chasteen, L ;
Sblattero, D ;
Marzari, O ;
Lou, JL ;
Siegel, R ;
Pavlik, P .
TRENDS IN BIOTECHNOLOGY, 2003, 21 (07) :312-317
[5]   Antibodies in proteomics I: generating antibodies [J].
Bradbury, A ;
Velappan, N ;
Verzillo, V ;
Ovecka, M ;
Chasteen, L ;
Sblattero, D ;
Marzari, O ;
Lou, JL ;
Siegel, R ;
Pavlik, P .
TRENDS IN BIOTECHNOLOGY, 2003, 21 (06) :275-281
[6]   Antibodies from phage antibody libraries [J].
Bradbury, ARM ;
Marks, JD .
JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 290 (1-2) :29-49
[7]  
Carmen Sara, 2002, Briefings in Functional Genomics & Proteomics, V1, P189, DOI 10.1093/bfgp/1.2.189
[8]   TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock [J].
Daubeuf, Bruno ;
Mathison, John ;
Spiller, Stephan ;
Hugues, Stephanie ;
Herren, Suzanne ;
Ferlin, Walter ;
Kosco-Vilbois, Marie ;
Wagner, Hermann ;
Kirschning, Carsten J. ;
Ulevitch, Richard ;
Elson, Greg .
JOURNAL OF IMMUNOLOGY, 2007, 179 (09) :6107-6114
[9]   Antibody arrays for high-throughput screening of antibody-antigen interactions [J].
de Wildt, RMT ;
Mundy, CR ;
Gorick, BD ;
Tomlinson, IM .
NATURE BIOTECHNOLOGY, 2000, 18 (09) :989-994
[10]   SELECTION AND APPLICATION OF HUMAN SINGLE-CHAIN FV ANTIBODY FRAGMENTS FROM A SEMISYNTHETIC PHAGE ANTIBODY DISPLAY LIBRARY WITH DESIGNED CDR3 REGIONS [J].
DEKRUIF, J ;
BOEL, E ;
LOGTENBERG, T .
JOURNAL OF MOLECULAR BIOLOGY, 1995, 248 (01) :97-105